Prosecution Insights
Last updated: November 04, 2026
Application No. 18/254,450

DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3- DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Non-Final OA §112
Filed
May 25, 2023
Priority
Nov 27, 2020 — CN 202011367513.8 +1 more
Examiner
FERGUSON, JALISA HOLMES
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suzhou Zelgen Biopharmaceuticals Co. Ltd.
OA Round
3 (Non-Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
24 granted / 39 resolved
+1.5% vs TC avg
Strong +41% interview lift
Without
With
+40.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
72
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
16.8%
-23.2% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
39.1%
-0.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 39 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/11/2026 has been entered. Status of the Claims Claims 1, 4 and 7-23 are pending. Claims 8 and 12-14 are rejected. Response to Amendment/Arguments The amendment filed 08/11/2026 is compliant with the requirements of 37 CFR 1.121(c), accordingly the amendment has been entered. Applicant' s arguments have been fully considered and are addressed below: Objection to the Claims The objection of claim 7 for informalities has been overcome by the amendment correcting said informalities. The objection has been withdrawn. 35 USC § 112 Rejections The rejection of claims 6, 8, and 12-14 under 35 USC 112 has been overcome by the amendments to said claims. The rejection has been withdrawn. 35 USC § 102 Rejection The rejection of claims 1-14 under 35 USC 102 for being anticipated by Gutcher et al. in WO 2018/046010 A1 has been overcome by the amendments to said claims. The rejection has been withdrawn. 35 USC § 103 Rejection The rejection of claims 1-6 and 9-11 under 35 USC 103 for being obvious over has been overcome by the amendments to said claims. The rejection has been withdrawn. New Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 8 and 12-14 are rejected under 35 U.S.C. 112(b) being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 8 recites the limitation "X" in the formulas (P-1) through (P-4) and (I). There is insufficient antecedent basis for this limitation in the claim. There is no definition of the variable X in the claim itself, nor in parent claim 1. Likewise, R1 of step (iv) and Formula (I) is not defined in claim 1. Applicant may amend the claim to more accurately reflect formula (III) of current claim 1. Dependent claims 12 and 14 are also rejected as indefinite for the same reason since they do not correct the indefiniteness issue of their parent claims. New Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 8 and 12-14 are rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 8 recites formula (I), which is broader than formula (III) of current claim 1 at the R1 position, as evidenced by the definition of R1 in the specification. See page 2. As a result, there is improper dependency. Applicant may amend the claim to more accurately reflect formula (III) of current claim 1. Claims 12-14 are rejected for the same reason since they do not correct the dependency issues of their parent claim. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jalisa H. Ferguson whose telephone number is (703)756-1489. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.H.F./Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

May 25, 2023
Application Filed
Oct 17, 2025
Non-Final Rejection mailed — §112
Jan 20, 2026
Response Filed
May 11, 2026
Final Rejection mailed — §112
Aug 11, 2026
Request for Continued Examination
Aug 12, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758641
BRM Targeting Compounds And Associated Methods Of Use
3y 0m to grant Granted Oct 13, 2026
Patent 12753187
AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
3y 3m to grant Granted Oct 06, 2026
Patent 12709602
INTERMEDIATES FOR MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
3y 5m to grant Granted Aug 18, 2026
Patent 12637415
LYOPHILIZED COMPOSITION COMPRISING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR INTRAVENOUS ADMINISTRATION AND THE USE THEREOF
4y 1m to grant Granted May 26, 2026
Patent 12599674
CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODS
9m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+40.8%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 39 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month